RapidPulse Emerges in the Ischemic Stroke Therapy Field

The company has raised $15 million in a series A round.

Omar Ford

June 23, 2021

1 Min Read
IMG_Jun232021at33528PM.jpg
GoodIdeas

There’s a new player in the Ischemic Stroke Therapy market. RapidPulse, a company spun out of Syntheon, a medical device incubator, has launched.

The Miami, FL-based company raised $15 million in a series A round to advance its RapidPulse Cyclic Aspiration System through expanded clinical evaluation and build out its platform of proprietary catheters.

RapidPulse said its device includes an aspiration pump to allow rapid and consistent removal of blood clots from the brain.

The financing was led by Santé Ventures who was joined by Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon.

“We are pleased to have partnered with an outstanding investor syndicate to move our RapidPulse technology forward in the clinic,” said Sean McBrayer, CEO of Syntheon who will also serve as initial CEO of RapidPulse. “Stroke is the second leading cause of death and the third leading cause of disability worldwide, and minutes matter in improving these outcomes. This investment will help us expand our clinical results and move towards regulatory approval in the U.S.”

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like